Much has been learned about SARS-CoV-2, the virus that causes the novel coronavirus, since the beginning of the COVID-19 pandemic. However, questions remain about the long-term impact of the virus on our bodies and brains. New research reported at the Alzheimer's Association International Conference® (AAIC®) 2021, held virtually and in Denver found associations between COVID-19 and persistent cognitive deficits, including the acceleration of Alzheimer's disease pathology and symptoms.
Children whose parents regularly smoke or vape marijuana may experience viral respiratory infections, such as the common cold, more frequently than those whose parents do not smoke, according to a study published in the journal Pediatric Research.
What The Study Did: Health care workers in Canada expressed their sources of distress and concern during the COVID-19 pandemic on an online forum.
What The Study Did: This review and meta-analysis investigated whether patients with mental health disorders are at increased risk of COVID-19-related death.
New research conducted in monkeys reveals that T cells are not critical for the recovery of primates from acute COVID-19 infections.
What The Study Did: Researchers examined the safety of the second dose of the Pfizer-BioNTech or Moderna COVID-19 vaccines in patients who experienced an allergic reaction to the first dose.
University of Washington scientists have developed a statistical framework that incorporates key COVID-19 data -- such as case counts and deaths due to COVID-19 -- to model the true prevalence of this disease in the United States and individual states. Their approach projects that in the U.S. as many as 60% of COVID-19 cases went undetected as of March 7, 2021, the last date for which the dataset they employed is available.
Canada should anticipate a resurgence of a childhood respiratory virus as COVID-19 physical distancing measures are relaxed, authors warn in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.210919.
How early is the course of COVID-19, mild or severe, determined? In Cell, researchers examined nasal cells sampled from patients at the time of diagnosis, looking for differences between those who developed severe disease and those who experienced a mild illness. Cells from patients who developed severe COVID-19 exhibited a more muted antiviral response. If the early stages of infection can determine disease severity, it opens a path for scientists to develop early therapeutic interventions.
There are many reasons that an intranasal vaccine against the SARS-CoV-2 virus would be helpful in the fight against COVID-19 infections, University of Alabama at Birmingham immunologists Fran Lund, Ph.D., and Troy Randall, Ph.D., write in a viewpoint article in the journal Science.